KPV Research Guide: The α-MSH Tripeptide & Inflammatory Signaling

What Is KPV?

KPV is a synthetic tripeptide composed of L-lysine, L-proline, and L-valine (Lys-Pro-Val; H-Lys-Pro-Val-OH). It corresponds to residues 11–13 — the C-terminal fragment — of alpha-melanocyte-stimulating hormone (α-MSH), which is itself derived from the proopiomelanocortin (POMC) precursor. For this reason it is also designated α-MSH(11-13).

What makes KPV interesting as a research input is that it appears to be a minimal anti-inflammatory pharmacophore of α-MSH: the short C-terminal motif retains much of the parent hormone's reported anti-inflammatory activity while lacking the core His-Phe-Arg-Trp (HFRW) sequence that α-MSH needs to bind melanocortin receptors. Because of that, KPV is reported to produce no pigmentary (melanotropic) effect, unlike full-length α-MSH. It is studied in cell and animal models of inflammation, and is a Research Use Only laboratory compound — not a drug, supplement, or therapeutic, with no approved human indication.

One housekeeping note on identity: in this catalog, "KPV10" denotes the KPV tripeptide supplied as a 10 mg lyophilized vial. Do not conflate it with unrelated numbered compounds that happen to share a similar label.

Mechanism of Action

The dominant reported mechanism for KPV is inhibition of NF-κB signaling through an intracellular, largely melanocortin-receptor-independent route. In intestinal epithelial and immune (T) cell models, nanomolar KPV has been reported to inhibit activation of NF-κB and MAP-kinase inflammatory pathways and to reduce pro-inflammatory cytokine output (IL-6, IL-12, TNF-α, IFN-γ). Mechanistically, this is associated with blocking IκBα phosphorylation/degradation, thereby preventing nuclear translocation of the p65 (RelA) NF-κB subunit (Dalmasso et al., 2008).

The PepT1 Transport Route

A key transport finding gives KPV a plausible path to its intracellular site of action. In the gut, KPV is reported to be taken up into epithelial and immune cells via the H+-coupled di/tripeptide transporter PepT1 (SLC15A1) — a transporter that is normally small-intestinal but is induced in the inflamed colon during inflammatory bowel disease. Consistent with transporter-mediated uptake rather than a receptor mechanism, the entry is competed by other di/tripeptides (for example Gly-Leu) and is not mediated by melanocortin receptors; notably, α-MSH itself did not reproduce the NF-κB inhibition in that model (Dalmasso et al., 2008).

A Receptor-Independent, IL-1β-Directed Profile

Independent work in a crystal-induced peritonitis model found that KPV's anti-inflammatory action is pharmacologically distinct from the core α-MSH peptides, is unlikely to act through melanocortin receptors, and instead appears to interfere with IL-1β-driven inflammation (Getting et al., 2003). Reviews of the α-MSH-peptide family note that the precise downstream signaling utilized by KPV is still not fully defined (Brzoska et al., 2010), so the details below the level of "NF-κB inhibition via cellular uptake" should be read as proposed rather than settled.

Separately from the anti-inflammatory mechanism, α-MSH and its KPV fragment have also been reported to carry direct antimicrobial activity against bacteria and Candida — an effect described as mechanistically distinct from the NF-κB-modulating action (Singh & Mukhopadhyay, 2014).

What the Research Literature Reports

The KPV evidence base is preclinical: it consists of in vitro work (intestinal epithelial cells, T cells, macrophages, keratinocytes) and in vivo rodent models (chemically-induced and transfer colitis, crystal-induced peritonitis). There are no robust, peer-reviewed controlled human efficacy trials for free KPV. The findings below are reported for context on what the published literature has observed; none of it is presented as a use indication for research-grade material.

The Foundational PepT1 / NF-κB Paper

The foundational mechanistic study reported that KPV is transported into intestinal epithelial and immune cells via PepT1 and, at nanomolar concentrations, inhibits NF-κB and MAP-kinase activation and reduces pro-inflammatory cytokines; in vivo, administered KPV reduced DSS- and TNBS-induced colitis in mice. Critically, the effect was PepT1-mediated and not melanocortin-receptor-mediated — α-MSH did not reproduce the NF-κB inhibition (Dalmasso et al., Gastroenterology, 2008; PMID 18061177).

Replication Across Colitis Models

A separate group reported anti-inflammatory effects of the melanocortin-derived tripeptide KPV in two murine IBD models — DSS colitis and CD45RB^hi T-cell transfer colitis — with earlier recovery, body-weight regain, reduced histological inflammation, and reduced colonic myeloperoxidase (MPO) activity. Importantly, protection persisted in MC1R-mutant (MC1R^e/e) mice, indicating the effect is at least partially independent of classical melanocortin-1-receptor signaling (Kannengiesser et al., Inflammatory Bowel Diseases, 2008; PMID 18092346).

Dissecting the Mechanism from Core α-MSH

In a crystal-induced peritonitis model, the C-terminal peptide KPV produced an anti-inflammatory effect pharmacologically distinct from the core α-MSH peptides, supporting a receptor-independent, IL-1β-directed mechanism rather than receptor agonism (Getting et al., Journal of Pharmacology and Experimental Therapeutics, 2003; PMID 12750433).

Reviews of the α-MSH-Peptide Family

A review establishing the structure-activity logic notes that KPV — the C-terminal tripeptide of α-MSH — lacks the sequence motif required to bind any known melanocortin receptor yet retains almost all of the anti-inflammatory capacity of the full hormone without pigmentary action, and that its precise signaling mechanism remains incompletely defined (Brzoska et al., Advances in Experimental Medicine and Biology, 2010; PMID 21222263). A second review describes α-MSH and KPV as combining anti-inflammatory and broad-spectrum antimicrobial activity (against Gram-positive and Gram-negative bacteria and Candida), states that the minimum sequence required for the anti-inflammatory activity of α-MSH is the C-terminal tripeptide KPV, and notes that KPV and the (CKPV)₂ analog act without melanotropic effect (Singh & Mukhopadhyay, BioMed Research International, 2014; PMID 25140322).

Reconstitution & Handling for Research

KPV is supplied as a lyophilized (freeze-dried) white powder and is reconstituted into solution before use in laboratory preparations. The handling notes below are grounded in standard lyophilized-peptide chemistry and general USP-type practice; they describe in-vitro/research handling only and imply no human-use directions.

• Equilibrate before opening. Bring the sealed vial to room temperature before breaking the seal, to limit condensation on the hygroscopic solid.
• Add solvent gently. KPV is a short, neutral-to-basic tripeptide (the lysine side chain is basic) and is generally water-soluble. For a fully dissolved stock, add sterile or bacteriostatic water slowly down the vial wall and let it dissolve without vigorous shaking — swirl gently and avoid foaming, which can shear peptide. If dissolution is sluggish, a trace of dilute acetic acid can aid solubility, but plain water is usually sufficient for KPV.
• Store cold and aliquot. Keep lyophilized powder desiccated at −20 °C (colder for long-term). After reconstitution, store aliquots refrigerated (2–8 °C) for short-term use or frozen at −20 °C for longer, and avoid repeated freeze–thaw cycles by aliquoting before freezing. Protect from light and air.
• Verify against the CoA. Confirm identity and purity by HPLC and mass spec per the lot Certificate of Analysis; research-grade material commonly reports purity around ≥98–99% HPLC along with net peptide content.

For concentration math, stock concentration (mg/mL) = peptide mass (mg) ÷ solvent volume (mL). For molar concentration, use the free-acid MW of ≈342.4 g/mol — so 1 mg/mL is roughly 2.92 mM for the free acid. Always confirm the exact form, salt, and net peptide content on your lot's CoA, since amidated C-termini or acetate/TFA salts change the effective molecular weight.

KPV vs α-MSH & Related Analogs

KPV is easy to misfile next to other peptides, so it helps to separate it cleanly by structure and mechanism.

KPV vs Full-Length α-MSH

KPV is just the C-terminal 3 residues (11–13) of α-MSH and lacks the core His-Phe-Arg-Trp (HFRW) melanocortin pharmacophore. As a result, unlike α-MSH it does not appreciably bind melanocortin receptors and produces no pigmentation or melanotropic effect — yet it retains most of α-MSH's reported anti-inflammatory capacity (Brzoska et al., 2010; Singh & Mukhopadhyay, 2014). That dissociation of anti-inflammatory activity from receptor binding is the whole reason KPV is studied as a "minimal" fragment.

KPV vs the Core / Central α-MSH Peptides

In peritonitis, KPV's anti-inflammatory profile is pharmacologically distinct and receptor-independent, consistent with an IL-1β-directed action rather than receptor agonism (Getting et al., 2003). In other words, the C-terminal fragment is not simply a weaker version of the central peptide — it appears to act through a different route.

KPV vs (CKPV)₂

(CKPV)₂ is a related cyclic/dimeric analog described as a more potent anti-inflammatory that has been advanced further in development (Singh & Mukhopadhyay, 2014). KPV10 as sold is the simple linear monomer — the two should not be treated as equivalent.

KPV vs Other Gut / Anti-Inflammatory Research Peptides

KPV is sometimes searched next to other research peptides studied in tissue-repair or gut contexts, such as BPC-157. These are mechanistically unrelated — KPV's signature is the α-MSH-fragment / NF-κB / PepT1 axis, which is specific to it — and cross-peptide efficacy comparisons in humans are not established. Treat any "this is like that" framing with caution.

Evaluating Research-Grade Supply

For reproducible work, the supply chain matters as much as the compound. When sourcing KPV for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For a short tripeptide like KPV, the COA should report:

• HPLC purity — research-grade KPV commonly tests ≥98%, ideally ≥99%.
• Mass-spec confirmation — verifying the measured mass is consistent with the expected Lys-Pro-Val identity, and confirming the exact form (free acid vs salt) so your reconstitution math is correct.
• Net peptide content, batch / lot number, and a recent test date linking the COA to your specific vial.

Elytra Labs publishes batch-specific third-party COAs for the research peptides we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret the chromatogram and mass-spec data.

2. Lyophilized Form and Cold-Chain Discipline

KPV should arrive as a lyophilized powder. Keep it desiccated and cold until reconstitution, and reconstitute with clean sterile or bacteriostatic water. A vendor that ships it properly and documents handling guidance is doing real quality control, not just shipping powder.

Frequently Asked Research Questions

What is KPV?

KPV is the C-terminal tripeptide (residues 11–13, Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH), which is derived from the POMC precursor. It is studied as a minimal anti-inflammatory fragment of the parent hormone in cell and animal models.

How does KPV work?

Its main studied action is inhibition of NF-κB signaling, reported to occur intracellularly and largely independently of melanocortin receptors — which is also why it has no pigmentary effect, unlike full α-MSH. In gut models, KPV is reported to enter epithelial and immune cells via the PepT1 di/tripeptide transporter, which is upregulated in the inflamed colon during IBD (Dalmasso et al., 2008).

What has KPV shown in animal models?

In rodent colitis models (DSS, TNBS, and CD45RB^hi T-cell transfer), administered KPV reduced inflammation, cytokine expression, and disease severity (Dalmasso et al., 2008; Kannengiesser et al., 2008). Protection was retained in MC1R-mutant mice, supporting a melanocortin-receptor-independent mechanism (Kannengiesser et al., 2008).

Is there human clinical evidence for KPV?

No. The evidence base is preclinical — cell and animal models — and there are no robust controlled human efficacy trials. KPV is a Research Use Only laboratory compound, not a drug or supplement, and no human dosing, therapeutic, or outcome claims are appropriate.

What does "research-grade" mean?

It indicates the peptide is intended for laboratory in vitro and animal-model investigation, synthesized in an appropriate facility, and accompanied by analytical documentation (purity, mass spec, batch records). It is not pharmaceutical- or human-grade and is not approved for human or veterinary therapeutic use.